Urinary tract infections are the second most common bacterial infections in the world. Most are easily treated with a short oral antibiotic course and resolve within days. But a growing subset — the complicated UTIs that reach the kidneys, invade the bloodstream, or are caused by multidrug-resistant Gram-negative bacteria — represent one of the most serious challenges in hospital medicine today. These are infections that can kill. And for years, physicians treating them have been watching the available antibiotic arsenal shrink as resistance to drug after drug has rendered once-reliable treatments useless.
That arsenal just received a meaningful addition. On May 29, 2026, the FDA approved Zaynich (cefepime and zidebactam), a novel intravenous antibiotic combination developed by Wockhardt, for the treatment of adult patients with complicated urinary tract infections (cUTI) — including acute pyelonephritis (kidney infection) — caused by susceptible Gram-negative pathogens. The approved organisms include Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae complex, and Pseudomonas aeruginosa — a list that encompasses the bacteria responsible for the most clinically dangerous and drug-resistant complicated UTIs in hospital settings.
"The threat of drug-resistant infections is an escalating crisis, leaving clinicians with fewer tools to treat patients facing these aggressive pathogens," said Dennis Deruelle, MD, Chief Medical Officer at Wockhardt. "The FDA approval of ZAYNICH is a monumental step forward in validating a new option for these underserved populations."
How Zaynich Works — and Why the Mechanism Is Genuinely New
Zaynich combines two distinct antibacterial molecules that work through separate and synergistic mechanisms. The first, cefepime, is a well-established fourth-generation cephalosporin that targets penicillin-binding proteins (PBPs) — the bacterial enzymes responsible for building and maintaining the cell wall. The second, zidebactam, is a non-beta-lactam antibacterial and beta-lactamase inhibitor — a genuinely novel class of molecule that serves two simultaneous functions: it inhibits beta-lactamases (the enzymes that destroy most beta-lactam antibiotics, including cefepime, before they can work), and it has independent antibacterial activity of its own by targeting PBP2, a different penicillin-binding protein than the ones cefepime attacks.
The result is a drug that attacks the bacterial cell wall through two distinct molecular pathways while simultaneously neutralizing the bacteria's primary resistance mechanism. This dual engagement — hitting PBP3 and PBP1a/b with cefepime and PBP2 with zidebactam, all while zidebactam disables beta-lactamases — creates a combined assault that drug-resistant bacteria cannot easily escape through the resistance pathways that have defeated individual agents.
This matters enormously for carbapenem-resistant Enterobacterales (CRE) and extended-spectrum beta-lactamase (ESBL)-producing organisms — two categories of bacteria that are resistant to most or all commonly used antibiotics and that are classified by the CDC as urgent threats. For patients hospitalized with UTIs or pyelonephritis caused by these organisms, the available treatment options before Zaynich's approval were limited to a small number of agents with significant toxicity, narrow efficacy, or limited availability.
What the Phase 3 ENHANCE-1 Trial Found
The FDA approval of Zaynich was based on data from the double-blind, Phase 3 ENHANCE-1 trial, which randomized hospitalized adults with complicated UTI or acute pyelonephritis 2:1 to receive either cefepime-zidebactam (2g cefepime plus 1g zidebactam) or meropenem 1g, each administered intravenously every 8 hours for 7 to 10 days. Meropenem is a carbapenem — one of the last-resort antibiotics currently used for serious drug-resistant Gram-negative infections. Zaynich achieved a higher composite clinical cure and microbiologic response rate than meropenem at the test-of-cure visit, meeting the non-inferiority primary endpoint and demonstrating superiority on the key secondary endpoint.
The clinical implication is significant: Zaynich can replace meropenem for complicated UTIs caused by susceptible organisms — and can treat infections that meropenem cannot, specifically those caused by carbapenem-resistant pathogens for which meropenem has no activity at all.
The drug has also received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA, both reflecting the agency's assessment that this drug addresses a serious unmet need in the anti-infective pipeline. Beyond the United States, Zaynich was approved by the Drugs Controller General of India on May 27, 2026, and Wockhardt has submitted a Marketing Authorization Application to the European Medicines Agency.
What This Means for Patients and Clinicians
Zaynich is an intravenous hospital drug — it is not available as an oral outpatient prescription and is intended for hospitalized patients with serious infections. Its availability expands the therapeutic options available to infectious disease specialists and hospital pharmacists treating patients for whom standard antibiotics have failed or for whom drug-resistant organisms are suspected or confirmed.
For the broader population concerned about drug-resistant UTIs, the approval of Zaynich is a concrete signal that the antibiotic pipeline — while still challenged — is producing new agents designed specifically to address the resistance patterns that are making common infections increasingly dangerous. The challenges of drug-resistant UTI are far from solved, but Zaynich represents a genuine and immediate advance.
Frequently Asked Questions
Q: What is Zaynich, and what is it approved for?
A: Zaynich (cefepime and zidebactam) is an intravenous antibiotic combination approved May 29, 2026 for complicated urinary tract infections, including acute pyelonephritis, caused by drug-resistant Gram-negative bacteria in adult hospital patients.
Q: What makes Zaynich different from existing antibiotics?
A: Zidebactam is a first-of-its-kind dual-function molecule: it inhibits beta-lactamase enzymes (the bacteria's main resistance weapon) while also attacking a distinct penicillin-binding protein (PBP2). Combined with cefepime's PBP3/PBP1a/b activity, Zaynich hits the bacterial cell wall at multiple targets while neutralizing resistance mechanisms.
Q: What bacteria does Zaynich treat?
A: E. coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae complex, and Pseudomonas aeruginosa — including carbapenem-resistant and ESBL-producing strains that other antibiotics cannot adequately address.
Q: Is Zaynich available as an oral pill?
A: No. Zaynich is an intravenous medication administered in hospital settings to patients with serious complicated UTIs or kidney infections. It is not an outpatient prescription drug.
Q: How did Zaynich perform against meropenem in clinical trials?
A: In the Phase 3 ENHANCE-1 trial, Zaynich achieved a higher composite clinical cure and microbiologic response rate than meropenem at the test-of-cure visit, meeting non-inferiority and demonstrating superiority on the key secondary endpoint.
